CClinicalTrials.gg
CompletedNCT02191280Updated Jul 16, 2014

Antistax® in Patients With Chronic Venous Insufficiency

A Phase 2 interventional study of Antistax®, low dose and Antistax®, high dose in Venous Insufficiency, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-07-16.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
25 Years to 75 Years
Sex
All
01

Study summary

Study to determine the efficacy and tolerability of two dose levels of Antistax relative to placebo in patients suffering from CVI grade I or incipient grade II

02

Conditions studied

  • Venous Insufficiency

Browse trials for

03

In context

Venous Insufficiency

189 studies on the registry are indexed under Venous Insufficiency; 16 are open to participants now.

This study's enrollment of 260 is above the median of 60 across 139 interventional studies indexed under Venous Insufficiency.

Browse Venous Insufficiency studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.

Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or female
  • Between 25 and 75 years of age
  • CVI I or CVI II (without expanded trophic disturbances)
  • Willing and able to give written informed consent prior to participation in the study

Exclusion criteria

Exclusion Criteria:

Concomitant disease(s) exclusion criteria:

  • Decompensated cardiac insufficiency
  • Edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal insufficiency, lymph edema, etc)
  • Peripheral arterial disease (ankle/arm pressure index \< 0.9)
  • Current acute phlebitis or thrombosis
  • Renal insufficiency (Serum creatinine > 1.5 mg/dl)
  • Liver disease (SGPT (ALAT) > 3x upper limit of normal)
  • Other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or hypocalcaemia, malignancies
  • Anamnestic indications of diabetic microangiopathy or polyneuropathy
  • Drug and/or alcohol abuse
  • Severe climacteric complaints
  • Immobility
  • Avalvulia
  • Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
  • State after pulmonary embolism
  • Recognized hypersensitivity to the trial drug ingredients
  • Current florid venous ulcus
  • Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compressive treatment, phlebectomy, etc.

Previous treatment(s) exclusion criteria:

  • Treatment with venous drugs within the last 4 weeks
  • Treatment with laxatives which affect fluid or electrolyte balance within the last 8 days
  • Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors or calcium antagonists within the last 8 days
  • Changes in post-menopausal Hormone replacement within the last 2 months

Concomitant treatment/non-drug therapy exclusion criteria:

  • Other venous drugs apart from the trial medication
  • Compression therapy
  • Venous surgery at the leg(s)
  • Extensive use (on more than a total of 6 days during the entire trial) of laxatives which affect fluid or electrolyte balance
  • Major surgery requiring full anesthesia

Other exclusion criteria:

  • Previously studied under this protocol
  • Participation in another clinical trial within the previous 90 days or during the present study
  • Patients who have visited a sauna or had other thermal applications in the previous day before any visit
  • Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
  • Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
  • Patients in a bad general health state according to the investigator's judgment
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
260 participants (actual)

Study arms

  • Experimental
    Antistax®, low dose

    Drug: Antistax®, low dose

  • Experimental
    Antistax®, high dose

    Drug: Antistax®, high dose

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugAntistax®, low dose
  • DrugAntistax®, high dose
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Changes from baseline of limb volume

    determined by water displacement

    Time frame: Baseline, day 84

Secondary outcomes

  1. Changes of limb volume

    determined by water displacement

    Time frame: Baseline, days 42 and 98

  2. Measurement of calf circumference

    in centimeters

    Time frame: Baseline, days 42, 84 and 98

  3. Measurement of ankle circumference

    in centimeters

    Time frame: Baseline, days 42, 84 and 98

  4. Assessment of subjective symptoms on a visual analogue scale (VAS)

    Time frame: Baseline, days 42, 84 and 98

  5. Assessment of global efficacy by patient on a 4-point verbal rating scale

    Time frame: days 42, 84 and 98

  6. Assessment of global efficacy by investigator on a 4-point verbal rating scale

    Time frame: days 42, 84 and 98

  7. Assessment of global tolerability by patient on a 4-point verbal rating scale

    Time frame: days 42, 84 and 98

  8. Assessment of global tolerability by investigator on a 4-point verbal rating scale

    Time frame: days 42, 84 and 98

  9. Number of patients with adverse events

    Time frame: up to 14 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM, Vargas E, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020 Nov 3;11(11):CD003229. doi: 10.1002/14651858.CD003229.pub4. PubMed 33141449 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02191280
Lead sponsor
Boehringer Ingelheim
Responsible party
Sponsor
First posted
Jul 16, 2014
Start date
Apr 1998
Primary completion
Sep 1998
Last update
Jul 16, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion